TITLE

BAL findings in a patient with pulmonary alveolar proteinosis successfully treated with GM-CSF

AUTHOR(S)
Schoch, O. D.; Schanz, U.; Koller, M.; Nakata, K.; Seymour, J. F.; Russi, E. W.; Boehler, A.
PUB. DATE
March 2002
SOURCE
Thorax;Mar2002, Vol. 57 Issue 3, p277
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: ldiopathic pulmonary alveolar proteinosis (PAP) has recently been recognised as a disease of impaired alveolar macrophage function caused by neutralising antigranutocyte-macrophage colony-stimulating (anti-GM-CSF) autoantibodies. Subcutaneous recombinant human GM-CSF is a novel treatment for PAP, but its mechanism of action is unclear. Methods: Clinical functional, and bronchoalveolar lavage (BAL) findings were prospectively evaluated in a patient with PAP treated with daily subcutaneous GM-CSF 8 μg/kg for 12 weeks. Result: Treatment resulted in improvement in dyspnoea, lung function, and peak cycle ergometry performance. In serum and BAL fluid the titre of anti-GM-CSF autoantibodies was raised at baseline and markedly reduced on treatment. At baseline the BAL fluid cellular profile showed a decrease in the absolute number and the percentage of macrophages (50%) and an increase in lymphocytes (45%), predominantly CD4+. This cellular distribution remained unchanged after 6 and 12 weeks of treatment while macrophages became morphologically normal and functionally improved. Extracellular proteinaceous material completely disappeared. Conclusions: Clinically successful treatment of PAP with GM-CSF was associate profound reduction in GM-CSF neutralising autoantibodies, improvement in alveolar macrophage morphology and function, but persistent BAL lymphocytosis.
ACCESSION #
12915262

 

Related Articles

  • Acute and Subacute Pulmonary Toxicity of Low Dose of Ultrafine Colloidal Silica Particles in Mice after Intratracheal Instillation. Kaewamatawong, Theerayuth; Shimada, Akinori; Okajima, Mina; Inoue, Hiromi; Morita, Takehito; Inoue, Kenichiro; Takano, Hirohisa // Toxicologic Pathology;2006, Vol. 34 Issue 7, p958 

    To study the acute and subacute lung toxicity of low dose of ultrafine colloidal silica particles (UFCSs), mice were intratracheally instilled with 0, 0.3, 3, 10, 30 or 100 μ g of UFCSs. Cellular and biochemical parameters in bronchoalveolar lavage fluid (BALF), histological alteration and...

  • bronchopulmonary lavage.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p322 

    An encyclopedia entry for "bronchopulmonary lavage, " which refers to the bronchoalveolar lavage, is presented.

  • Bronchoalveolar Lavage: Role in the Pathogenesis, Diagnosis, and Management of Interstitial Lung Disease. Daniele, Ronald P.; Elias, Jack A.; Epstein, Paul E.; Rossman, Milton D. // Annals of Internal Medicine;Jan85, Vol. 102 Issue 1, p93 

    Discusses the status of bronchoalveolar lavage as an investigative tool and assesses its advantages and limitations in the clinical setting. Assessment of interstitial lung diseases by lavage; Information on the lavage procedure; Constituents of normal airways.

  • The Calcareous Lung. Krishnakurup, Jayakrishnan; Abdelsayed, George // Mayo Clinic Proceedings;Feb2011, Vol. 86 Issue 2, p85 

    The article presents a case study of an 84-year-old woman who was admitted for aortic valve replacement and was diagnosed for a pulmonary alveolar microlithiasis (PAM) due to the presence of microliths in the bronchoalveolar lavage sample.

  • Increased Endothelin-1 Levels of BAL Fluid in Patients with Behçet's Disease. Hamzaoui, Kamel; Chelbi, Hanene; Kamoun, Mariam; Dhifallah, Imen Ben; Hamzaoui, Agnes // Mediators of Inflammation;2007, Vol. 2007, Special section p1 

    Objective and background. Pulmonary aneurysms and thrombosis constitute a significant cause of morbidity and mortality in Behçet's disease (BD). Various factors have been studied to explore the pathogenesis of vascular involvement in BD. As endothelin (ET) is known for its potent...

  • Haemosiderin-Laden Sputum Macrophages for Diagnosis in Pulmonary Veno-Occlusive Disease. Lederer, Heidi; Muggli, Bettina; Speich, Rudolf; Treder, Ula; Stricker, Hans; Goede, Jeroen; Ulrich, Silvia; Stämpfli, Simon F.; Breitenstein, Alexander // PLoS ONE;Dec2014, Vol. 9 Issue 12, p1 

    Aims: Pulmonary veno-occlusive disease (PVOD) is a rare condition of pulmonary arterial hypertension (PAH), in which post-capillary veins are affected. Since the therapeutic approach in PVOD differs from other forms of PAH, it is crucial to establish the diagnosis. Due to the fact that affected...

  • Elevation of soluble interleukin-2 receptor levels in the bronchoalveolar lavage from patients with systemic sclerosis. Martinez, José Antônio Baddini; Nishimura, Cinthya; Guatura, Sandra; Sato, Emilia; King Jr., Talmadge E. // Rheumatology International;Nov2001, Vol. 21 Issue 3, p122 

    This study was designed to investigate the levels of IL-2 and its soluble receptor (sIL-2R) in bronchoalveolar lavage fluid (BALF) from patients with systemic sclerosis (SSc). We studied 18 patients with SSc and 10 healthy volunteers. Based on high-resolution computed tomography lung scans the...

  • Bronchoalveolar Lavage in the Diagnosis of Diffuse Pulmonary Infiltrates in the Immunosuppressed Host. Stover, Diane E.; Zaman, Muhammad B.; Hajdu, Steven I.; Lange, Michael; Gold, Jonathan; Armstrong, Donald // Annals of Internal Medicine;Jul84, Vol. 101 Issue 1, p1 

    Presents information on a study which examined the usefulness of bronchoalveolar lavage in the diagnosis of pulmonary infiltrates in the immunosuppressed patient. Materials and methodology of the study; Results and discussion.

  • BAL.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p233 

    An encyclopedia entry for the acronym "BAL," which stands for British antilewisite or bronchoalveolar lavage, is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics